Pharming Group NV (PHAR): Price and Financial Metrics
GET POWR RATINGS... FREE!
PHAR Stock Price Chart Interactive Chart >
PHAR Price/Volume Stats
|Current price||$7.32||52-week high||$12.56|
|Prev. close||$7.86||52-week low||$6.71|
|Day high||$8.20||Avg. volume||5,067|
|50-day MA||$8.45||Dividend yield||N/A|
|200-day MA||$9.19||Market Cap||476.85M|
Pharming Group NV (PHAR) Company Bio
Pharming Group NV is a biopharmaceutical company involved with the development, production and commercialization of human therapeutic proteins to be used in highly innovative therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage, and surgical/traumatic bleeding.
Most Popular Stories View All
PHAR Latest News Stream
|Loading, please wait...|
PHAR Latest Social Stream
View Full PHAR Social Stream
Latest PHAR News From Around the Web
Below are the latest news stories about Pharming Group NV that investors may wish to consider to help them evaluate PHAR as an investment opportunity.
Zacks Investment Research downgraded shares of Pharming Group from a hold rating to a strong sell rating in a research note issued to investors on Tuesday morning, Zacks.com
Good morning, investor!
Pharming Group NV (NASDAQ: Full story available on Benzinga.com
Pharming announces positive results of Phase II/III pivotal clinical study of leniolisib for the treatment of activated PI3K delta syndrome
Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/NASDAQ: PHAR) announces positive results from the pivotal Phase II/III blinded randomized, placebo-controlled registration-enabling study of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) also known as PASLI (p110δ-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency).
Pharming receives positive EMA decision on paediatric investigation plan (PIP) for leniolisib in Europe
Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) announces that a positive decision has been made by the European Medicines Agency (EMA) on the Paediatric Investigation Plan (PIP) for leniolisib, a phosphoinositide 3-kinase (PI3K) inhibitor, currently in development for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS).
PHAR Price Returns